Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Every day ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Welcome to the Rani Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple milestones anticipated in 2025 including: FDA meeting ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ...

Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN FRANSCISCO ...

March 29 (Reuters) - U.S. President Donald Trump is urging senior advisers to take a more aggressive stance on tariffs as the administration prepares for a major escalation in its global trade war ...

Shares of Pliant Therapeutics PLRX have plunged 88.5% in the past three months following recent setbacks in the clinical ...